shutterstock_193931348 shutterstock_193931348

ACLA Applauds CMS Decision to Delay New Payment System, Evaluating Final PAMA Rule

shutterstock_193931348 shutterstock_193931348

House Agriculture-FDA Appropriations Bill Includes Report Language Directing FDA Suspend Efforts to Finalize LDT Guidance

shutterstock_193931348 shutterstock_193931348

Bipartisan House Ways and Means Committee Letter Sent to CMS

Health Subcommittee Chairman Tiberi, Representatives Meehan and Pascrell sent a bipartisan letter urging CMS to delay PAMA changes to the Clinical Laboratory Fee Schedule.

Read More »
JoinACLA_banner JoinACLA_banner


Learn about the benefits of joining the nation’s leading advocacy organization for clinical laboratories.

alanslider alanslider

ACLA Warns Against Duplicative LDT Regulation at House Hearing

At a recent Energy and Commerce Health Subcommittee hearing, ACLA President Alan Mertz cautioned that duplicative regulation of LDTs would be harmful to innovation and patient access to diagnostic services.

Read More »
pama slider pama slider

The Protecting Access to Medicare Act of 2014

Big changes are coming to how Medicare pays for clinical lab services – here’s everything your lab needs to know about the new law. 

Learn More »

View all news & updates » Recent News & Updates

View all news & updates »

Policy Issues

  • Reimbursement and Coverage

    Medicare cuts to clinical labs threaten jobs, stifle innovation, and put patient access to vital lab tests at risk.

    Continue Reading »

  • Laboratory Developed Tests

    FDA regulation of laboratory-developed tests (LDTs) is duplicative, outside of FDA jurisdiction, and would negatively impact patient access to vital lab tests.

    Continue Reading »

  • IOAS Exception

    Self-referral leads to over-utilization, mistreated patients, and billions of wasted Medicare dollars. It’s time to close the loophole.

    Continue Reading »

View all policy issues »